
BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target
BioMarin Pharmaceutical (BMRN) Analyst Ratings
Bulls say
BioMarin Pharmaceutical demonstrated a positive financial trajectory with Voxzogo, recording a 9% quarter-over-quarter increase and a substantial 56% year-over-year revenue growth, reaching $735 million. The company's guidance for 2025 reflects an expected revenue growth rate of approximately 10% year-over-year, while operating margins are projected to expand to 32-33%, indicating improved profitability. Additionally, ongoing investment in research and development, particularly for the Voxzogo expansion and promising preclinical results, positions BioMarin favorably in the competitive landscape of therapies for rare genetic diseases.
Bears say
The financial analyst identifies several fundamental concerns contributing to a negative outlook on BioMarin Pharmaceutical's stock. Key issues include potential regulatory setbacks and pricing risks associated with ValRox, increased competition in the PKU market, and a declining base business that may hinder revenue growth. Additional risks stem from the execution of the drug pipeline, uncertainties regarding successful drug launches, and broader macroeconomic challenges affecting the biotechnology sector.
This aggregate rating is based on analysts' research of BioMarin Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
BioMarin Pharmaceutical (BMRN) Analyst Forecast & Price Prediction
Start investing in BioMarin Pharmaceutical (BMRN)
Order type
Buy in
Order amount
Est. shares
0 shares